PDCD1 and cancer: Immune checkpoint inhibitors (ICIs) targeting programmed cell death-1 (PD-1), programmed death ligand-1 (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) have revolutionized cancer therapy by restoring antitumor immunity.